SLU-PP-332 + 5-Amino-1MQ (Capsule)

Description

This synergistic metabolic blend combines SLU-PP-332 (an ERRalpha/gamma agonist that mimics endurance exercise at the molecular level) with 5-Amino-1MQ (an NNMT inhibitor that raises cellular NAD+ levels), creating a comprehensive approach to metabolic optimization through two distinct but complementary pathways. SLU-PP-332 activates the ERR transcription factor network to drive mitochondrial biogenesis and fat oxidation, while 5-Amino-1MQ inhibits NNMT to raise NAD+ and activate the AMPK/sirtuin axis. Together, these two compounds address metabolic health from both the transcriptional level (ERR agonism programming cells to burn more fat) and the coenzyme level (NAD+ supporting the enzymatic machinery of fat oxidation). This combination is particularly relevant for individuals seeking fat loss, improved metabolic health, and mitochondrial optimization without appetite suppression or stimulant effects. Both compounds have demonstrated meaningful metabolic improvements in preclinical models, and their mechanisms are non-overlapping, suggesting additive or synergistic effects.

Key Characteristics

Investigated Benefits

• Synergistic fat loss
• Mitochondrial biogenesis
• Increased NAD+
• AMPK activation
• Exercise-like metabolic adaptations

* Benefits based on preclinical/animal research unless otherwise noted.

Mechanism of Action

“A synergistic metabolic blend combining ERR agonism and NNMT inhibition for comprehensive fat loss and metabolic health.”

SLU-PP-332 activates ERRalpha and ERRgamma nuclear receptors, which regulate hundreds of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. This creates a transcriptional program that increases mitochondrial density, enhances fat burning capacity, and promotes metabolically active muscle fiber types — essentially the molecular signature of endurance exercise adaptation. 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that depletes NAD+ and SAM in adipose tissue. By inhibiting NNMT, 5-Amino-1MQ raises cellular NAD+ levels, which activates SIRT1 and other sirtuins that regulate fat storage gene expression, and activates AMPK, which promotes fatty acid oxidation and inhibits lipogenesis. The combination provides complementary metabolic activation: SLU-PP-332 drives the transcriptional machinery of fat oxidation, while 5-Amino-1MQ provides the coenzyme substrate (NAD+) and signaling molecule (AMPK) needed to execute that program efficiently.

Reconstitution Guide

Research Highlights

1. 1Both components demonstrated metabolic benefits in animal models
2. 2Complementary mechanisms provide synergistic metabolic activation
3. 3NNMT inhibition and ERR agonism target distinct but complementary pathways

Compatible Peptides

Peptides commonly used alongside SLU-PP-332 + 5-Amino-1MQ (Capsule) for synergistic effects.